Access Study Assessing the Safety of Choline Tracers for Positron Emission Tomography (Choline-PET)

November 13, 2026 updated by: Jean-Mathieu Beauregard

Choline-PET: Access Study Assessing the Safety of Choline Tracers for Positron Emission Tomography

The purpose of this study is primarily to make choline-PET clinically available at CHU de Québec - Université Laval, while assessing the safety of non-Health-Canada-approved choline tracers. Our hypothesis is that these tracers are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of choline-PET will be explored in our clinical setting.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

5000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Quebec
      • Québec, Quebec, Canada, G1R2J6

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Reception of a procedure request for Choline-PET by a referring physician.
  2. Age ≥ 18 y.o.

Exclusion Criteria:

  1. Incapacity to provide informed consent
  2. Pregnancy, unless there has been a discussion between the participant and a nuclear medicine physician investigator about the potential clinical benefits vs. the potential risks for the fetus, in the context of the participant's medical condition, and that this discussion is documented in the nuclear medicine physician's clinical report.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Choline pet

Administration of a choline tracer for PET

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants with choline PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .
Time Frame: Up to 1 week

From the moment the participants received the choline PET radiopharmaceuticals

Up to 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean-Mathieu Beauregard, MD, CHU de Quebec-Universite Laval

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2036

Study Completion (Estimated)

December 1, 2037

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2026-8572

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe